08048035968
ELEFTHA 150MG Injection wholesale and global supplier from India to Australia | Phoenix Exim.

1. General Information

Eleftha 150mg Injection is an intravenous targeted cancer therapy containing trastuzumab. It is designed to target cancer cells that overexpress the HER2 (human epidermal growth factor receptor 2) protein. The medicine is administered by qualified healthcare professionals in a hospital or oncology setting.

Brand: Eleftha
Strength: 150mg
Active ingredient: Trastuzumab
Dosage form: Injection/IV infusion
Manufacturer: Intas Pharmaceuticals Ltd.
Therapeutic category: Targeted anticancer monoclonal antibody
Storage: Refrigerated, generally 2°C–8°C; follow the product's approved storage instructions.

2. Product Information

Eleftha 150mg is supplied as a lyophilized powder for concentrate for intravenous infusion. Official Indian pricing documentation identifies trastuzumab 150mg as the active ingredient in Eleftha 150mg Injection.

The treatment schedule and dose are determined by the oncologist according to the patient's cancer type, body weight, treatment regimen, previous therapies and clinical condition.

3. Uses of Eleftha 150mg Injection

Eleftha may be prescribed for:

  • HER2-positive breast cancer
  • Certain early-stage or metastatic HER2-positive breast cancers
  • HER2-positive gastric cancer
  • HER2-positive gastroesophageal-junction cancer, particularly advanced/metastatic disease in appropriate treatment combinations.

HER2 testing is generally required to determine whether trastuzumab-based treatment is appropriate.

4. Benefits of This Medicine

The principal therapeutic benefit of Eleftha is its targeted action against HER2-positive cancer cells.

Potential benefits include:

  • Helps inhibit HER2-mediated cancer-cell growth.
  • Can slow progression of HER2-positive cancers.
  • May be used as part of combination cancer-treatment regimens.
  • Provides targeted therapy for cancers with HER2 overexpression.
  • May help reduce the risk of recurrence in certain treatment settings when prescribed appropriately.

The expected benefit varies considerably depending on the cancer stage and the overall treatment plan.

5. Side Effects of Eleftha 150mg Injection

Possible adverse effects include:

  • Infusion-related reactions
  • Fever or chills
  • Nausea
  • Headache
  • Fatigue
  • Cough
  • Rash
  • Diarrhea
  • Infections
  • Changes in blood-cell counts
  • Heart-related complications
  • Lung complications.

Some reactions can be serious. Patients should immediately inform their healthcare team about severe breathlessness, chest symptoms, swelling, persistent cough, severe allergic reactions or other unusual symptoms.

6. Common Side Effects

Commonly reported effects include:

  • Fever
  • Chills
  • Headache
  • Nausea
  • Fatigue or weakness
  • Cough
  • Rash
  • Infection
  • Diarrhea
  • Insomnia
  • Anemia or reduced blood-cell counts
  • Mouth inflammation/stomatitis.

Not every patient experiences these effects, and their severity can vary.

7. How to Use Eleftha 150mg Injection

Eleftha must be administered only by a qualified healthcare professional. It is given through an intravenous infusion and should not be self-administered.

The oncologist determines:

  1. Appropriate dose based on the treatment protocol.
  2. Frequency of administration.
  3. Infusion duration.
  4. Whether other anticancer medicines should be given alongside it.
  5. Necessary monitoring during treatment.

Patients should attend all scheduled oncology appointments and should not change or discontinue treatment without medical advice.

8. How Eleftha 150mg Works

Eleftha contains trastuzumab, a recombinant IgG1 monoclonal antibody. It binds to the HER2 receptor on cancer cells. HER2 can promote cancer-cell growth when it is overexpressed.

By binding to HER2, trastuzumab interferes with HER2-related growth signals and also helps the immune system recognize and attack HER2-expressing cancer cells. This targeted mechanism can help slow the growth and progression of HER2-positive cancers.

9. Safety Advice

  • Prescription use: Use only under the supervision of an oncologist.
  • Heart health: Tell your doctor about existing heart disease or previous cardiac treatment because trastuzumab can cause cardiac complications.
  • Lung problems: Report new or worsening cough or breathing difficulties promptly.
  • Infusion reactions: Patients should be monitored during and after administration, particularly during initial infusions.
  • Pregnancy: Trastuzumab can harm an unborn baby; pregnancy should be discussed with the treating physician before therapy.
  • Breastfeeding: Discuss breastfeeding with your healthcare professional before treatment.
  • Drug interactions: Tell the oncology team about all prescription medicines, OTC medicines and supplements being used.
  • Laboratory monitoring: Doctors may monitor blood counts and heart function during treatment.
  • Storage: Maintain the required cold-chain conditions; the product should generally be refrigerated at 2°C–8°C and protected according to its approved product instructions.

10. Frequently Asked Questions

Q1. What is Eleftha 150mg Injection?
Eleftha 150mg is a trastuzumab-containing targeted monoclonal antibody used for certain HER2-positive cancers.

Q2. What is the composition of Eleftha 150mg?
It contains trastuzumab 150mg as the active ingredient.

Q3. What cancers can Eleftha treat?
It is primarily used for certain HER2-positive breast cancers and HER2-positive gastric/gastroesophageal-junction cancers.

Q4. Is Eleftha 150mg a chemotherapy medicine?
It is more specifically a targeted monoclonal-antibody therapy, rather than a conventional cytotoxic chemotherapy drug.

Q5. How is Eleftha administered?
It is administered intravenously by a trained healthcare professional.

Q6. Can I administer Eleftha at home?
No. It should be administered under appropriate medical supervision.

Q7. Does Eleftha require refrigeration?
Yes. Product information indicates refrigerated storage, generally 2°C–8°C.

Q8. What is the main active ingredient?
The active ingredient is trastuzumab.

Q9. What should I do if I experience breathing difficulty during treatment?
Inform the healthcare professional immediately. Breathing difficulties can indicate an infusion reaction or a more serious cardiac or pulmonary complication.

Q10. Are there substitutes for Eleftha 150mg?
Several trastuzumab 150mg products may be available, but substitution should be made only after confirmation by the treating doctor or pharmacist.

11. Substitute for Eleftha 150mg Injection

Examples of trastuzumab 150mg alternatives listed by Indian medicine references include:

  • Hertraz 150mg Injection
  • Trasturel 150mg Injection
  • Trumab 150mg Injection
  • Neuzumab 150mg Injection
  • Immuvac 150mg Injection
  • Other locally approved trastuzumab products may also be available.

Important: A substitute should not be selected solely on price. The oncologist should confirm the appropriate trastuzumab product, strength, formulation, indication and treatment protocol.

12. SEO Keywords

Primary keywords:

  • Eleftha 150mg Injection
  • Eleftha 150mg Injection exporter
  • Eleftha 150mg supplier
  • Eleftha 150mg wholesaler
  • Eleftha 150mg distributor
  • Eleftha 150mg Trastuzumab Injection
  • Trastuzumab 150mg Injection exporter
  • Trastuzumab 150mg supplier from India
  • Eleftha 150mg medicine exporter India
  • Eleftha 150mg pharmaceutical exporter

Long-tail B2B keywords:

  • Eleftha 150mg Injection exporter from India
  • Eleftha 150mg Trastuzumab Injection wholesale supplier
  • Eleftha 150mg Injection international pharmaceutical supplier
  • Eleftha 150mg Injection bulk supplier from India
  • Eleftha 150mg Injection wholesale exporter Nagpur India
  • Genuine Eleftha 150mg Injection supplier from India
  • Eleftha 150mg Injection supplier for international markets
  • Trastuzumab 150mg Injection wholesale exporter India
  • Eleftha 150mg anticancer medicine exporter
  • Eleftha 150mg Injection pharmaceutical wholesale supplier

Target-market keywords:

  • Eleftha 150mg Injection exporter to USA
  • Eleftha 150mg Injection exporter to UK
  • Eleftha 150mg Injection exporter to Australia
  • Eleftha 150mg Injection exporter to Canada
  • Eleftha 150mg Injection exporter to Singapore
  • Eleftha 150mg Injection exporter to South Korea
  • Eleftha 150mg Injection exporter to UAE
  • Trastuzumab 150mg supplier from India to USA
  • Trastuzumab 150mg supplier from India to UK
  • Trastuzumab 150mg global pharmaceutical supplier
Aug 22nd, 2026 1:00 PM

Keywords